7 min read By now, your news feed, your dinner table conversations, and your doctor’s office have been flooded with chatter about the meds approved for weight loss known as semaglutide (e.g. Ozempic) and tirzepatide (e.g.Mounjaro, Zepbound). Now, there’s a new peptide in town: retatrutide. Yes, all of these chemicals are technically peptides, and each
4 min read THERE'S BEEN A wave of new therapies for Alzheimer’s disease released over the last few years. But nothing would be as revolutionary as simply taking a pill to slow down cognitive decline. Better yet, the ideal medication would be a pill that could protect people with a genetic risk for Alzheimer's. That's
You don't have permission to access "http://www.medpagetoday.com/primarycare/exercisefitness/118071" on this server. Reference #18.2a153b17.1761134531.39a511c6 https://errors.edgesuite.net/18.2a153b17.1761134531.39a511c6
10 min read MOST GUYS GO about their business in the gym with one of two goals: They either want to build strength or gain muscle (or just as likely, they hope to achieve a bit of both). To achieve either of those outcomes, they can't just show up and perform random exercises assuming they'll
This common "fact" about dementia isn't actually true. Shutterstock According to 2020 data published in the journal Alzheimer's & Dementia, there are currently about 5.8 million people aged 65 years or older with dementia in the United States alone. And researchers expect that number to increase to roughly 13.8 million people by 2050—more than double…
Pros Has a sturdy, 11-gauge steel build Supports up to 500 pounds Costs less than $100 Cons Only comes with a straight bar Sticks out two feet from the wall We like the Titan Fitness Adjustable Depth Pull-Up Bar because it’s sturdy, bare-bones, and relatively affordable. The mounting is a touch more complicated than doorway-mounted
Duodenal mucosal resurfacing (DMR) — an investigational endoscopic procedure — helped patients maintain weight loss, and in some cases, even lose additional weight, 3 months after discontinuing GLP-1 receptor agonist therapy, initial results of the open-label, multistage REMAIN-1 trial showed. In addition, “the procedure was well tolerated, with only minor, transient TEAEs [treatment-emergent adverse events]
Please complete security verification This request seems a bit unusual, so we need to confirm that you're human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and hold the button If you believe this is an error, please contact our support team. 185.149.70.50 : bb5fc4aa-bed0-4235-92bb-bc988778